Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06382051
Other study ID # CAIN457ACA06
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 28, 2024
Est. completion date April 30, 2025

Study information

Verified date April 2024
Source Novartis
Contact Novartis Pharmaceuticals
Phone +41613241111
Email novartis.email@novartis.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada. Patients will be enrolled in the study for up to 66 days and will be asked to fill-out a PsA screening questionnaire at their first dermatologist visit. Patients screening positive for PsA will have a second visit with a rheumatologist where a full PsA diagnosis assessment will be performed. A remote 'end of study' (EOS) visit will be conducted by the dermatologist to document the patient's biologic Disease-Modifying Antirheumatic Drugs (bDMARDs) treatment choice and status.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 502
Est. completion date April 30, 2025
Est. primary completion date April 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Key inclusion criteria: 1. Moderate-to-severe plaque PsO patients who are candidates for bDMARDs, as per provincial reimbursement criteria 2. Adult patients at the time of informed consent signature 3. Patients able to understand and willing to comply with protocol requirements, instructions, and restrictions 4. Residents of Canada Key exclusion criteria: 1. Patients who have previously screened positive for PsA through PEST or any other screening method 2. Patients who have been diagnosed with PsA and/or followed by a rheumatologist 3. Patients who have been diagnosed with inflammatory arthritis unrelated to PsA (rheumatoid arthritis, reactive arthritis, enteropathic arthritis, axial spondyloarthritis) 4. Patients treated with a bDMARD for moderate-to-severe plaque PsO or any other medical condition

Study Design


Intervention

Diagnostic Test:
PEST Screening group
PEST Screening group

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Outcome

Type Measure Description Time frame Safety issue
Primary Positive Predictive Value (PPV) for PEST and PEST+2 in adult patients with moderate-to-severe plaque PsO who are candidates for bDMARDs To assess the impact of adding two questions (morning stiffness and low back or buttock pain) to the validated PEST for the potential diagnosis of PsA in moderate-to-severe plaque PsO patients who are candidates for biologic disease-modifying antirheumatic drugs (bDMARDs) The primary clinical question of interest is: Can the addition of two questions to PEST pertaining to presence of morning stiffness and low back or buttock pain (i.e., PEST+2) allow for improved screening and diagnosis of PsA in patients with moderate-to-severe plaque PsO? Up to approximately 1 year
Secondary Proportion of patients scoring negative on PEST and positive on PEST+2 with a confirmed new PsA diagnosis or suspicion of PsA by a rheumatologist To estimate the proportion of patients with a confirmed or suspected PsA diagnosis referred by dermatologists using PEST+2 only Up to approximately 1 year
Secondary Proportion of patients with a confirmed new PsA diagnosis or suspicion of PsA by a rheumatologist Proportion of patients with a new PsA diagnosis or suspicion of PsA, confirmed by the rheumatologist who scored:
Negative on PEST and positive on PEST+pictures
Negative on PEST+2 and positive on PEST+pictures+2 will be evaluated to assess the impact of adding pictures as reference to guide patients answering the screening questions (question 1, 3, and 5)
Up to approximately 1 year
Secondary Proportion of patients with a false positive score between each group Proportion of patients with false positive score between each group will be evaluated:
PEST+2 vs. PEST+pictures+2
PEST+pictures vs. PEST
PEST+pictures+2 vs. PEST
Up to approximately 1 year
Secondary Description of the baseline characteristics of the positive screening score and negative screening score patients for both PEST and PEST+2 tests Description of the baseline characteristics (i.e., patient age, biological sex, years since plaque PsO diagnosis, medical history, disease characteristics, concomitant treatments, height, weight, etc.) of the positive screening score and negative screening score patients for both PEST and PEST+2 tests will be evaluated to determine patient's baseline characteristics. Up to approximately 1 year
Secondary Patient acceptability/user experience of the PEST+2 questionnaire Summary scores of the patient acceptability questionnaire of PsA screening questionnaires and a categorical presentation of question-by-question responses at Visit 1 Up to approximately 1 year
Secondary Administration of dermatologist quantitative surveys Administration of dermatologist quantitative surveys, as well as open-ended qualitative questions to assess the acceptability and feasibility of the PEST+pictures+2 from the perspective of dermatologists Up to approximately 1 year
Secondary Qualitative interview with selected dermatologists Brief 1:1 qualitative interview with selected dermatologists (maximum 12) to assess their knowledge, beliefs, and attitudes towards PsA screening (e.g., motivation to screen) Up to approximately 1 year
Secondary Intervention Appropriateness Measure (IAM) To assess the appropriateness of the PEST+2 from the perspective of rheumatologists Up to approximately 1 year
See also
  Status Clinical Trial Phase
Completed NCT04152759 - Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects Phase 1
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT01925768 - Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis Phase 3
Completed NCT01892436 - Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis Phase 3
Completed NCT01212770 - PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Phase 3
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT01212757 - PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Phase 3
Completed NCT03953378 - CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis
Recruiting NCT02572700 - Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis
Completed NCT02556034 - Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT02188654 - Metformin in Psoriatic Arthritis N/A
Completed NCT02164214 - Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)? Phase 3
Completed NCT01392326 - Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) Phase 3
Completed NCT01083693 - Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs N/A
Not yet recruiting NCT00517101 - Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy N/A
Completed NCT00133315 - TNFalfa Blocking Treatment of Spondylarthropathies Phase 4
Completed NCT00659412 - A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis Phase 2
Completed NCT00946686 - To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions Phase 1
Not yet recruiting NCT06059430 - Cohort Project of Patients With Inflammatory Rheumatism